Search Results - "Bhuva D"

Melia dubia Cav.: a new folivory record of Indian flying fox (Pteropus medius Temminck).

Authors: Thakur, N. S. Bhuva, D. C. Patel, Minal H. et al.

Source: Current Science (00113891). 1/25/2025, Vol. 128 Issue 2, p206-209. 4p.

The Role of Visceral Adipose Tissue and Subcutaneous Tissue on Intestinal Ultrasound Visualization and Disease Activity in Pediatric Inflammatory Bowel Disease.

Authors: Kellar, A. Bhuva, D. George, T. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1843-i1845. 3p.

SYNTHESIS AND ANTIMICROBIAL EVALUTION OF SOME NOVEL SUBSTITUTED THIAZOLE DERIVATIVES.

Authors: Vagadia, F. J. Bhuva, D. A. Jiladia, M. A.

Source: Pharma Science Monitor. Nov2012 Supply2, Vol. 3 Issue 4, p2633-2642. 10p.

SYNTHESIS AND ANTIMICROBIAL EVALUTION OF SOME NOVEL SUBSTITUTED BENZOFURAN DERIVATIVES.

Authors: Bhuva, D. A. Vagadia, F. J. Jiladia, M. A.

Source: Pharma Science Monitor. Nov2012 Supply2, Vol. 3 Issue 4, p2623-2632. 10p.

Root sucker technique for successful clonal multiplication of Melia dubia Cav. without sacrifice of mother tree.

Authors: Thakur, N. S. Hegde, H. T. Chauhan, R. S. et al.

Source: Current Science (00113891). 11/10/2021, Vol. 121 Issue 9, p1235-1237. 3p.

Inhibitory and stimulatory effects of Melia dubia cav. drupe pulp on Capsicum annuum L. and Vigna radiata L. in laboratory and pot culture bioassays.

Authors: Purohit, B. K. Thakur, N. S. Kumar, Sanjeev et al.

Source: Allelopathy Journal. Mar2022, Vol. 55 Issue 2, p207-222. 16p.

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Authors: Beas-Lozano EL Scagliarini S Valdez-Sandoval PI et al.

Source: Frontiers in immunology [Front Immunol] 2026 Apr 20; Vol. 17, pp. 1805104. Date of Electronic Publication: 2026 Apr 20 (Print Publication: 2026).

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Authors: Maruzzo M Poprach A Buti S et al.

Source: Minerva urology and nephrology [Minerva Urol Nephrol] 2026 Apr; Vol. 78 (2), pp. 210-221.

Publication Type: Journal Article; Comparative Study; Multicenter Study

Journal Info: Publisher: Edizioni Minerva Medica Country of Publication: Italy NLM ID: 101777299 Publication Model: Print Cited Medium: Internet ISSN: 2724-6442 (Electronic) Linking ISSN: 27246051 NLM ISO Abbreviation: Minerva Urol Nephrol Subsets: MEDLINE

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.

Authors: Sreenath ND Pandalanghat S Kapoor A et al.

Source: BMC cancer [BMC Cancer] 2025 Aug 18; Vol. 25 (1), pp. 1337. Date of Electronic Publication: 2025 Aug 18.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

Authors: Bourlon MT Galli L Grande E et al.

Source: Frontiers in oncology [Front Oncol] 2025 Jul 25; Vol. 15, pp. 1605282. Date of Electronic Publication: 2025 Jul 25 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).

Authors: Santoni M Roviello G Grande E et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 27; Vol. 74 (7), pp. 225. Date of Electronic Publication: 2025 May 27.

Publication Type: Journal Article; Comparative Study; Multicenter Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.

Authors: Roviello G Molina-Cerrillo J Massari F et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Jan 03; Vol. 74 (2), pp. 65. Date of Electronic Publication: 2025 Jan 03.

Publication Type: Journal Article; Multicenter Study; Comparative Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Authors: Santini D Li H Roviello G et al.

Source: Targeted oncology [Target Oncol] 2024 Nov; Vol. 19 (6), pp. 893-903. Date of Electronic Publication: 2024 Sep 17.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

Authors: Incorvaia L Monteiro FSM Massari F et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jun 04; Vol. 73 (8), pp. 142. Date of Electronic Publication: 2024 Jun 04.

Publication Type: Journal Article; Multicenter Study; Observational Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.

Authors: Monteiro FSM Fiala O Massari F et al.

Source: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Apr; Vol. 22 (2), pp. 305-314.e3. Date of Electronic Publication: 2023 Nov 24.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.

Authors: Massari F Mollica V Kopp RM et al.

Source: European urology focus [Eur Urol Focus] 2025 Sep; Vol. 11 (5), pp. 736-746. Date of Electronic Publication: 2025 Jul 29.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101665661 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-4569 (Electronic) Linking ISSN: 24054569 NLM ISO Abbreviation: Eur Urol Focus Subsets: MEDLINE

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).

Authors: Santoni M Massari F Myint ZW et al.

Source: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Oct; Vol. 21 (5), pp. e309-e319.e1. Date of Electronic Publication: 2023 Mar 20.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.

Authors: Porta C Bamias A Zakopoulou R et al.

Source: Minerva urology and nephrology [Minerva Urol Nephrol] 2023 Aug; Vol. 75 (4), pp. 460-470.

Publication Type: Observational Study; Multicenter Study; Journal Article

Journal Info: Publisher: Edizioni Minerva Medica Country of Publication: Italy NLM ID: 101777299 Publication Model: Print Cited Medium: Internet ISSN: 2724-6442 (Electronic) Linking ISSN: 27246051 NLM ISO Abbreviation: Minerva Urol Nephrol Subsets: MEDLINE

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.

Authors: Santoni M Massari F Myint ZW et al.

Source: Targeted oncology [Target Oncol] 2023 Jul; Vol. 18 (4), pp. 559-570. Date of Electronic Publication: 2023 Jun 27.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Authors: Santoni M Buti S Myint ZW et al.

Source: European urology oncology [Eur Urol Oncol] 2024 Feb; Vol. 7 (1), pp. 102-111. Date of Electronic Publication: 2023 Jul 21.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE